InsiderTrades

Form 4 for ATYR aTYR PHARMA INC

Accepted 2023-02-06 00:00:00 ET · period of report 2023-02-03 · accession 0001209191-23-007364 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-02-06 2023-02-03 ATYR Broadfoot Jill Marie CFO M - OptEx — +3,750 17.0K +28% —
D 2023-02-06 2023-02-06 ATYR Broadfoot Jill Marie CFO S - Sale+OE $2.36 -1,566 15.5K -9% -$3,696
D 2023-02-06 2023-02-03 ATYR Broadfoot Jill Marie CFO M - OptEx $0.00 -3,750 11.2K -25% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common stock 2023-02-03 M A 3,750 — 17,026 D — — (F2) Restricted stock units convert into common stock on a one-for-one basis. (F3) Includes 986 shares acquired under that Company's 2015 Employee Stock Purchase Plan on November 15, 2022.
2 Common Common stock 2023-02-06 S D 1,566 $2.36 15,460 D — —
3 Derivative Restricted Stock Unit 2023-02-03 M D 3,750 $0.00 11,250 D — · — to — 3,750 Common Stock (F2) Restricted stock units convert into common stock on a one-for-one basis. (F5) The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.